Faculty

Institution

Unit

Venue

Vivian Oehler

Associate Professor

University of Washington

Affiliations

School of Medicine

Hematology and Oncology

Vivian Oehler is currently serving as a Hematology And Oncology Associate Professor at University of Washington.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Vivian Oehler

University of Washington

Associate Professor

You can click a keyword to filter the displayed items

oncology hematology medicine pharmacology cancer research medicinal research cancer treatment hematological malignancies dermatology chronic myeloid leukemia genetics cancer care leukemia cancer biology therapeutic efficacy pharmacotherapy laboratory medicine cancer genetics gene expression acute myeloid leukemia clinical trials cancer genomics myeloid neoplasia molecular diagnostics tumor biology outcomes research molecular cancer cellular therapy cancer management clinical transplantation disease progression drug trials hemostasis regenerative medicine lymphoid neoplasia tyrosine kinase inhibitors cell transplantation protein science vascular biology prognosis rna biology genome biology medical mycology cancer cells medical genetics jama oncology clinical mycology cell therapy stem cell transplantation gene function transplantation medicine anti-cancer agents myeloid leukemia high-dose cytarabine epigenetic changes blood cells pharmacokinetics microarray data analysis tumor targeting translational bioinformatics receptor tyrosine kinases clinical practice guidelines prognostic significance chronic phase dose-escalated mitoxantrone acute lymphoblastic leukemia leukemia stem cells gene regulation cytogenetics drug safety stem cell mobilization older patients acute myelogenous leukemia first-in-human trial chronic myelogenous leukemia polymerase chain reaction pathology gene expression profiling translational research cell biology cancer discovery systems biology

Video Presentations

Notable Scholarly Works

Notable Federal Grants

Collaborators

Abstract 732: Toward Optimizing Cxcr4 Inhibition With Beta Adrenergic Blockade to Enhance Chemotherapy Response in Acute Myeloid Leukemia. Cancer Research (2024)

Brenda LoeraChunxiao ZhangPina M. CardarelliNiña G. CaculitanSylvia ChienJin DaiVivian G. OehlerJianying ZhangGuido MarcucciPamela S. Becker

medicineanti-cancer agentsclinical researchcancer biologychemotherapy responsecancer researchpharmacokineticsneurologypharmacologycancer treatmentoncologypharmacotherapycellular therapycancer careacute myeloid leukemiacancer immunotherapydrug discoverybeta adrenergic blockadeenzyme inhibitiontherapeutic efficacymedicinal research

Chronic Myeloid Leukemia, Version 2.2024, Nccn Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network (2024)

Neil P. ShahRavi BhatiaJessica K. AltmanMaria AmayaKebede H. BegnaEllin BermanOnyee ChanJoan ClementsRobert H. CollinsPeter T. CurtinDaniel J. DeAngeloMichael DrazerLori ManessLeland MethenySanjay MohanJoseph O. MooreVivian OehlerKeith PratzIskra PusicMichal G. RoseWilliam ShomaliB. Douglas SmithMichael StylerMoshe TalpazTiffany N. TanakaSrinivas TantravahiJames ThompsonSteven TsaiJennifer VaughnJeanna WelbornDavid T. YangHema SundarKristina Gregory

clinical practice guidelinespharmacologyoncologychronic myeloid leukemiahematology

Combined Cxcr-4 Inhibition With Novel Agent Gpc-100 (Burixafor) and Beta 2 Adrenergic Receptor Blockade Enhances Cytarabine Response for Acute Myeloid Leukemia Blasts on Stroma. Blood (2024)

Yueming TangAdam BraunZachary von BehrenJieya WuCaitlyn HaleyChunxiao ZhangBrenda LoeraPina M. CardarelliNina CaculitanSylvia ChienJin DaiVivian G. OehlerJianying ZhangGuido MarcucciPamela S. Becker

platelet antagonistpharmacologycancer immunotherapyreceptorsmalignant blood disordersoncogenesoncologyhematological malignanciesradiation oncologyleukemiapharmacotherapybiomolecular engineeringcellular therapymedicinal researchimmune checkpoint inhibitorsmyeloid neoplasiahematologytherapeutic targets

Dose-Adjusted Epoch Plus Inotuzumab Ozogamicin in Adults With Relapsed or Refractory B-Cell All. JAMA Oncology (2024)

Noam E. KopmarKim QuachTed A. GooleyChristen H. MartinoSindhu CherianMary-Elizabeth M. PercivalAnna B. HalpernCristina M. GhiuzeliVivian G. OehlerJanis L. AbkowitzRoland B. WalterRyan D. Cassaday

cancer immunotherapycancer treatmentmedicinedose-adjusted epochcancer researchoncologyradiation oncologyleukemiarefractory b-cellcancer carehematological malignanciesjama oncologyinotuzumab ozogamicinepidemiology

Dose Modifications in the Management of Chronic Phase Chronic Myeloid Leukemia: Who, What, and When. Journal of the National Comprehensive Cancer Network (2024)

Vivian G. OehlerIvan J. HuangChloe SiuMiryoung KimJessie SignorelliChristopher S. BellGabriela S. Hobbs

early detectioninhibitory activitylung cancerfunctional modificationgliomascarcinogenesisvascular biologydose modificationsneurologykidney cancermedical mycologytreatment effectsbrain tumor researchimmunologyprostate cancerurologyspecific resistanceoncogenesmedicinal research

Efficacy and Safety of Bosutinib in Previously Treated Patients With Chronic Myeloid Leukemia: Final Results From the Byond Trial. Leukemia (2024)

Carlo Gambacorti-PasseriniTim H. BrümmendorfElisabetta AbruzzeseKevin R. KellyVivian G. OehlerValentín García-GutiérrezHenrik Hjorth-HansenThomas ErnstEric LeipSimon PurcellGerald LuscanAndrea ViqueiraFrancis J. GilesAndreas Hochhaus

neurologypharmacologyclinical trialsoutcomes researchmedicinecancer treatmenttreatment effectsbyond trialoncologylaboratory medicinechronic myeloid leukemiadrug trialspharmacotherapytherapeutic efficacyclinical researchmedicinal researchhematologycohort studies

Intensive Re-Induction Chemotherapy Followed by Early Allogeneic Hematopoietic Cell Transplant for Relapsed/Refractory High-Grade Myeloid Neoplasms. Transplantation and cellular therapy (2024)

Noam E. KopmarMegan OthusKim QuachAllegra RasmussenKelda SchonhoffPamela S. BeckerRoland B. WalterAnna B. HalpernRachel SalitRyan D. CassadayAndrei ShustovF. Marc StewartVivian G. OehlerBart L. ScottBrenda M. SandmaierStephanie J. LeeElihu H. EsteyMary-Elizabeth M. Percival

transplant surgerymedicineclinical transplantationtransplantation medicinecell transplantationintensive re-induction chemotherapyhematologycancer researchhaematopoiesisbone marrow transplantationcancer treatmentoncologycellular therapyimmunologycell therapycancer careorgan transplantationradiation oncologymyeloid neoplasia

Management and Outcomes of Patients Diagnosed With Chronic Myeloid Leukemia in Blast Phase: A Multicenter Analysis by the H Jean Khoury Cure CML Consortium. Blood (2024)

Akriti G. JainKinaya SmithUmar IqbalGenevieve M CraneLing ZhangJay YangEllen K. RitchieAlice MimsSrinivas K TantravahiTalha BadarLindsay A.M. ReinVivian G. OehlerJerald P. RadichB. Douglas SmithVamsi K. KotaJorge E. CortesAnthony M. HunterOnyee ChanJavier Pinilla-IbarzMichael W. DeiningerSudipto MukherjeeKendra L. SweetEhab L. AtallahZhuoer Xie

outcomes researchthrombosissurvival analysissurgical oncologyhematologycancer researchchronic myeloid leukemiabone marrow transplantationemergency medicinecancer treatmentoncologymulticenter analysisblast phasehematological malignanciescancer careepidemiologycancer managementurologymalignant blood disordersleukemiamyeloid neoplasia

Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib. JAMA Oncology (2024)

Elias JabbourVivian G. OehlerPaul B. KollerOmer JamyElza LomaiaAnthony M. HunterOlga UspenskayaSvetlana SamarinaSudipto MukherjeeJorge E. CortesMaria R. BaerVera ZherebtsovaVasily ShuvaevAnna TurkinaIgor DavydkinHuanshan GuoZi ChenTommy FuLixin JiangCunlin WangHengbang WangDajun YangYifan ZhaiHagop Kantarjian

tyrosine kinase inhibitorsmedicinereceptor tyrosine kinasesdrug resistancecancer researchtumor biologyanticoagulantsvascular biologyjama oncologypharmacologycancer treatmentoncologypharmacotherapyimmunologyenzyme inhibitiontherapeutic efficacymedicinal researchnovel therapiesneuropharmacology

Olverembatinib (Hqp1351) Overcomes Resistance/Intolerance to Asciminib and Ponatinib in Patients (Pts) With Heavily Pretreated Chronic-Phase Chronic Myeloid Leukemia (Cp-CML): A 1.5-Year Follow-Up Update With Comprehensive Exposure-Response (E-R) Analyses. Blood (2024)

Elias JabbourOmer JamyPaul B. KollerVivian G. OehlerMaria R. BaerElza LomaiaAnthony M. HunterOlga UspenskayaSvetlana SamarinaJorge E. CortesSudipto MukherjeeDennis Dong Hwan KimVera ZherebtsovaVasily ShuvaevAnna TurkinaIgor DavydkinHuanshan GuoZi ChenHengbang WangTommy FuLixin JiangZhihong YangCunlin WangDajun YangYifan ZhaiHagop Kantarjian

pharmacologymalignant blood disorderscancer treatmentmedicineclinical transplantationinfectious diseasesdrug resistanceoncologytherapy resistancehematological malignanciesantimicrobial resistancesurvival analysisleukemiapharmacotherapymyeloid neoplasiahematology

1
2
3
4
5
15
10 / page

Vivian Oehler

Associate Professor

University of Washington

Affiliations

School of Medicine

Hematology and Oncology

Vivian Oehler is currently serving as a Hematology And Oncology Associate Professor at University of Washington.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Vivian Oehler

University of Washington

Associate Professor

You can click a keyword to filter the displayed items

Video Presentations

Notable Scholarly Works

Notable Federal Grants

Collaborators

Abstract 732: Toward Optimizing Cxcr4 Inhibition With Beta Adrenergic Blockade to Enhance Chemotherapy Response in Acute Myeloid Leukemia. Cancer Research (2024)

Brenda LoeraChunxiao ZhangPina M. CardarelliNiña G. CaculitanSylvia ChienJin DaiVivian G. OehlerJianying ZhangGuido MarcucciPamela S. Becker

Chronic Myeloid Leukemia, Version 2.2024, Nccn Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network (2024)

clinical practice guidelinespharmacologyoncologychronic myeloid leukemiahematology

Combined Cxcr-4 Inhibition With Novel Agent Gpc-100 (Burixafor) and Beta 2 Adrenergic Receptor Blockade Enhances Cytarabine Response for Acute Myeloid Leukemia Blasts on Stroma. Blood (2024)

Yueming TangAdam BraunZachary von BehrenJieya WuCaitlyn HaleyChunxiao ZhangBrenda LoeraPina M. CardarelliNina CaculitanSylvia ChienJin DaiVivian G. OehlerJianying ZhangGuido MarcucciPamela S. Becker

Dose-Adjusted Epoch Plus Inotuzumab Ozogamicin in Adults With Relapsed or Refractory B-Cell All. JAMA Oncology (2024)

Noam E. KopmarKim QuachTed A. GooleyChristen H. MartinoSindhu CherianMary-Elizabeth M. PercivalAnna B. HalpernCristina M. GhiuzeliVivian G. OehlerJanis L. AbkowitzRoland B. WalterRyan D. Cassaday

Dose Modifications in the Management of Chronic Phase Chronic Myeloid Leukemia: Who, What, and When. Journal of the National Comprehensive Cancer Network (2024)

Vivian G. OehlerIvan J. HuangChloe SiuMiryoung KimJessie SignorelliChristopher S. BellGabriela S. Hobbs

Efficacy and Safety of Bosutinib in Previously Treated Patients With Chronic Myeloid Leukemia: Final Results From the Byond Trial. Leukemia (2024)

Intensive Re-Induction Chemotherapy Followed by Early Allogeneic Hematopoietic Cell Transplant for Relapsed/Refractory High-Grade Myeloid Neoplasms. Transplantation and cellular therapy (2024)

Management and Outcomes of Patients Diagnosed With Chronic Myeloid Leukemia in Blast Phase: A Multicenter Analysis by the H Jean Khoury Cure CML Consortium. Blood (2024)

Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib. JAMA Oncology (2024)

1
2
3
4
5
15
10 / page

Similar Faculty Members

Roland Walter

Institution

University of Washington

hematological malignancies

cell therapy

Jerald P. Radich

Institution

University of Washington

human genetics

pathology

Alexander E Perl

Institution

University of Pennsylvania

oncogene

hematological malignancies

Ramiro Garzon

Institution

University of Utah

molecular cancer

pathology

Peter Greenberg

Institution

Stanford University

hematology

medicine

David Claxton

Institution

Pennsylvania State University

metabolomics

hematological malignancies

Christopher R Cogle

Institution

University of Florida

hematology

medicine

Megan Othus

Institution

University of Washington

prognosis

cancer registration

Azra Raza

Institution

Columbia University

histopathology

aplastic anemia

Soheil Meshinchi

Institution

University of Washington

leukemia biology

stem cell

Similar Faculty Members

Roland Walter

Institution

University of Washington

hematological malignancies

cell therapy

Jerald P. Radich

Institution

University of Washington

human genetics

pathology

Alexander E Perl

Institution

University of Pennsylvania

oncogene

hematological malignancies

Ramiro Garzon

Institution

University of Utah

molecular cancer

pathology

Peter Greenberg

Institution

Stanford University

hematology

medicine

David Claxton

Institution

Pennsylvania State University

metabolomics

hematological malignancies

Christopher R Cogle

Institution

University of Florida

hematology

medicine

Megan Othus

Institution

University of Washington

prognosis

cancer registration

Azra Raza

Institution

Columbia University

histopathology

aplastic anemia

Soheil Meshinchi

Institution

University of Washington

leukemia biology

stem cell